Nycomed Expands In Turkey, Despite Tough Pharma Environment
This article was originally published in PharmAsia News
Executive Summary
Swiss pharmaceutical manufacturer Nycomed has acquired rights from specialty pharmaceutical company Biomeks Ilac (Biomeks) to market a portfolio of over ten pharmaceutical products in Turkey
You may also be interested in...
Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey
Swiss drug maker Nycomed Pharma AS aims to increase revenues from emerging markets by 150% by 2015. The Zurich-based private equity-owned company has seen double-digit growth in Russia and Latin American markets in the past year, and now it is preparing for more deal-making from Moscow and a major product launch in Turkey to accelerate the growth
Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey
Swiss drug maker Nycomed Pharma AS aims to increase revenues from emerging markets by 150% by 2015. The Zurich-based private equity-owned company has seen double-digit growth in Russia and Latin American markets in the past year, and now it is preparing for more deal-making from Moscow and a major product launch in Turkey to accelerate the growth
Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey
The Swiss drug company has set a goal of generating 60% of sales in emerging markets by 2015.